Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued.
*The design of the infusor used in this study was different from the FUROSCIX On-Body Infusor, but it used the same administration profile.
†90% confidence interval of 94.8-104.8.
See how patients successfully used FUROSCIX at home.
Learn MoreReferences: 1. Sica DA, Muntendam P, Myers RL, et al. Subcutaneous furosemide in heart failure: pharmacokinetic characteristics of a newly buffered solution. JACC Basic Transl Sci. 2018;3(1):25-34. Published 2018 Feb 7. doi:10.1016/j.jacbts.2017.10.001. 2. FUROSCIX [prescribing information]. Burlington, MA: scPharmaceuticals Inc.; 2022.